The TREM2-DAP12 signaling pathway in Nasu–Hakola disease: a molecular genetics perspective

Junjie Xing1,2
Amanda R Titus1
Mary Beth Humphrey1–3
1 Department of Medicine, 2 Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, 3 Department of Veteran’s Affairs, Oklahoma City, OK, USA

Abstract: Nasu–Hakola disease or polycystic lipomembranous osteodysplasia with sclerosing leukencephalopathy (PLOSL) is a rare recessively inherited disease that is associated with early dementia and bone cysts with fractures. Here, we review the genetic causes of PLOSL with loss-of-function mutations or deletions in one of two genes, TYROBP and TREM2, encoding for two proteins DNAX-activating protein 12 (DAP12) and triggering receptor expressed on myeloid cells-2 (TREM2). TREM2 and DAP12 form an immunoreceptor signaling complex that mediates myeloid cell, including microglia and osteoclasts, development, activation, and function. Functionally, TREM2-DAP12 mediates osteoclast multi-nucleation, migration, and resorption. In microglia, TREM2-DAP12 participates in recognition and apoptosis of neuronal debris and amyloid deposits. Review of the complex immunoregulatory roles of TREM2-DAP12 in the innate immune system, where it can both promote and inhibit pro-inflammatory responses, is given. Little is known about the function of TREM2-DAP12 in normal brain homeostasis or in pathological central nervous system diseases. Based on the state of the field, genetic testing now aids in diagnosis of PLOSL, but therapeutics and interventions are still under development.

Keywords: polycystic, leukencephalopathy, Alzheimer’s, lipomembranous, dementia, microglia

Introduction – clinical characteristics and pathology of Nasu–Hakola disease

Nasu–Hakola disease, also known as polycystic lipomembranous osteodysplasia with sclerosing leukencephalopathy (PLOSL), is a rare autosomal recessive leukodystrophy characterized by progressive early-onset dementia and recurrent bone fractures due to polycystic osseous lesions. In the early 1970s, Nasu and Hakola both independently described the disease.1,2 Thus far, about 200 cases have been diagnosed worldwide. Most cases have been from Finland and Japan, but there is a global distribution.3

The disease course is generally divided into four stages: latent, osseous, early neurologic, and late neurologic.4 After normal childhood development (latent stage), the disease begins manifesting during adolescence or young adulthood with polyarthralgias. The osseous stage is typically between ages 15 years and 30 years when patients develop pain in the hands, wrists, ankles, and feet followed by recurrent low-trauma bone fractures. Fractures occur in location of polycystic osseous and osteoporotic lesions in the limb bones. During the early neurologic stage, most often in the third or fourth decades of life, patients develop personality changes characteristic of a frontotemporal dementia (FTD). Initially, they experience mild memory disturbances and personality
changes followed by progressive memory deficits. Generalized seizures are frequently observed. In the late neurologic stage, patients progress to a profound dementia and become bedridden. PLOSL leads to a progressive dementia that usually is fatal during the fifth decade of life. Occasionally, the disease presents with the neurologic symptoms preceding the osseous ones; therefore, early unexplained leukoencephalopathy warrants limb X-rays to aid in the diagnosis. Unfortunately, there is no curative treatment for the disease, and management is supportive including antiepileptic drugs to prevent seizures. Although pathological fractures occur and osseous lesion may be painful, conservative management is usually recommended.

The combination of early-onset FTD starting in the third or fourth decade and radiographic demonstration of cystic bone lesions is unique and facilitates the differentiation of PLOSL from other forms of familial and nonfamilial FTD. A biopsy of bone lesions is not necessary to confirm the diagnosis of PLOSL in the setting of this unique presentation. Radiographic imaging of PLOSL is characterized by lytic lesions in the distal bones of the extremities, most often in the metaphyseal and epiphyseal regions.

During the course of the disease, trabecular bone loss develops in the distal portions of the long bones as well as symmetrical cystic lesions in the carpal and tarsal bones, heads of the metatarsals and metacarpal bones, and phalanges of the hand and feet. The lesions are often painful and frequently lead to pathologic fractures. The polyostotic lytic lesions may be surrounded by sclerotic rims or can be ill defined. Computed tomography (CT) imaging of the lytic lesions often shows smooth, marginated cystic lesions. Magnetic resonance imaging (MRI) of the osteolytic lesions reveals fat-equivalent content. If the bony lesions are biopsied, there is generally replacement of the marrow by fatty tissue separated by folded membranes which stain positive for periodic acid Schiff. Interestingly, these membranocystic lesions are seen not only in the bone marrow but also in systemic adipose tissues of the subepicardium, mediastinum, adrenal glands, testes, hepatic sinusoids, and pulmonary vascular lumens. Such lesions are characteristic of PLOSL but not specific for this disease and are seen in lipomembranous panniculitis and ischemic necrosis of fat.

The occurrence of lipomembranous cystic lesion adipose tissues suggests a systemic inflammatory state, although this has not been clinically apparent in PLOSL patients.

As discussed above, PLOSL also results in a profound and rapidly progressive FTD with associated seizures. Brain CT and MRI reveal atrophy of the cerebral white matter, and frontal and polar regions of the temporal lobes are most affected.

On MRI, there is thinning of the corpus callosum and ventricular enlargement not attributable to atrophy. Bilateral calcifications of the basal ganglia are often found on CT imaging. Positron emission tomography scanning reveals decreased glucose metabolism in the frontal white matter and basal ganglia suggesting a state of hypometabolism. On histologic examination, there is loss of axons and myelin, as well as fibriillary gliosis. Areas of demyelination with accumulation of lipid granules termed sudanophilic leukodystrophy may be present around vessels and inside tissue. The axons are swollen and deformed into spheroid shapes termed axonal spheroids. In the spinal cord, neuronal loss and destruction of neuronal cell bodies or chromatolysis are seen in the anterior horn. Microgli activation in the frontal and temporal white matter areas is also prominent. Additionally, there is an accumulation of lipid-laden macrophages and free fatty acids in the brain. In the majority of patients, vascular abnormalities are seen in the deep frontal and temporal white matter. There is concentric thickening of the vascular walls of affected small arterioles and capillaries. The constellation of these clinical and histological characteristics has suggested a lipodystrophy, although none has been associated with PLOSL.

Genetic causes of Nasu–Hakola disease

Over the last decade, tremendous achievements have been made in the understanding of the molecular aspect of Nasu–Hakola. Paloneva et al were the first to report the association of TYROBP mutations with PLOSL in 2000.

They found that presenile dementia with bone cysts in Finnish patients was associated with loss-of-function mutations in TYROBP at chromosome 19q13.1. TYROBP contains five exons encoding DNAX-activating protein 12 (DAP12), a transmembrane signaling adapter protein found in a variety of immune cells. They subsequently reported the association of mutations in TREM2, encoding an immunoreceptor, triggering receptor expressed on myeloid cells-2 (TREM2), in several additional families with PLOSL. This was the first report of loss-of-function mutations in two proteins of the same signaling complex leading to the same disease.

DAP12 is a 12 kDa, 113-amino acid (aa), transmembrane adaptor protein which is composed of a 27 aa leader, 14 aa extracellular domain, 24 aa transmembrane domain, and a 48 aa cytoplasmic region. TREM2 is a 40 kDa, 230 aa membrane glycoprotein with a single extracellular immunoglobulin-like ligand-binding domain, a transmembrane domain, and a short cytoplasmic tail without a signaling motif.
A transmembrane domain positively charged lysine (aa186) of TREM2 couples to negatively charged aspartic acid residue in the transmembrane domain of DAP12 through electrostatic interactions (Figure 1). In addition to TREM2, DAP12 associates with a variety of immunoglobulin-like receptors, such as TREM-1 (TREM1) and signal-regulatory protein beta 1 (SIRPβ1), as well as lectin receptors including myeloid DAP12-associating lectin 1 (MDL1). In the initial report of genetic association of PLOSL with TYROBP, 26 patients were found to carry a homozygous genomic deletion of 5,265 bp encompassing the 5′ UTR and exons 1–4 of TYROBP (Table 1). This deletion results in no detectable DAP12. Additional point mutations in exons 1, 3, or 4 have been identified that produce truncated or nonfunctional DAP12 (Table 1). Klunemann et al also reported a 14 aa insertion in DAP12. Interestingly, one Japanese patient has been identified with compound heterozygous mutations in TYROBP, each with a point mutation predicted to produce nonfunctional truncated DAP12 polypeptides. Thus, deletion or production of nonfunctional DAP12 is associated with PLOSL.

Additional analysis of ~20% of Nasu–Hakola patients having normal TYROBP revealed a surprising finding that they had deletions or mutations in TREM2 (Table 1). The TREM2 gene, found at human chromosome 6p21.1, consists of five exons encoding TREM2, a transmembrane cell surface receptor found on many myeloid cells including macrophages, dendritic cells, osteoclasts (OCs), and

Figure 1 Multimeric or high-affinity ligand-induced TREM2 signaling promotes myeloid cell activation.

Notes: In response to high-affinity ligand binding to heavily glycosylated TREM2, Src family kinases phosphorylate the two tyrosines within ITAM of DAP12 and the YINM motif of DAP10, which forms docking sites for the Syk and PI3K. PI3K converts PI3P to PI4P leading to the recruitment of LAB adapter protein and multiple signaling effectors including SLP-76, PLCγ2, AKT, VAV3, Tec kinases, and Grb2. This signaling complex then leads to the activation of ERK, CARD9, calcineurin, ROS, and calcium flux. These signals increase activation and nuclear localization of transcription factors AP1, NF-κB, and NFAT to promote cell proliferation, cell survival, phagocytosis, pro-inflammatory cytokine production, and cytoskeletal rearrangement.

Abbreviations: TREM2, triggering receptor expressed on myeloid cells-2; ITAM, immunoreceptor tyrosine-based activation motif; DAP10, DNAX-activating protein 10; Syk, spleen tyrosine kinase; PI3K, phosphatidylinositol-3-kinase; SLP-76, src homology 2 domain-containing leukocyte protein of 76 kDa; PLCγ2, phospholipase C gamma-2; Grb2, growth factor-receptor-bound protein 2; ROS, reactive oxygen species; NFAT, nuclear factor activated T cell; SOS1, son of sevenless homolog1; DAG, diacylglycerol; IP3, inositol-1,4,5-trisphosphate; PKC, protein kinase C; RasGRP, Ras guanyl nucleotide-releasing protein; CaMK, calmodulin-dependent kinase.
microglia. Each of these patients had one of several point mutations that are predicted to lead to a truncated TREM2 protein or to a specific aa change in the transmembrane domain leading to inability of TREM2 to couple to DAP12 (Table 1). PLOS1 families with mutations in *TREM2* have been described in the USA, Sweden, Italy, Norway, and Bolivia (Table 1). Thus, multiple mutations within *TREM2* that lead to nonfunctional TREM2 proteins are associated with PLOS1.

Paloneva et al have further investigated other DAP12-associated receptors for genetic association with PLOS1 and excluded TREM1, lymphocyte antigen-95 homolog (Ly95), SIRPβ1, MDL1, CD94, killer immunoglobulin-like receptor 2DS2 (KIR2DS2), and NKG2C (CD159c). Downstream intracellular kinases, spleen tyrosine kinase (Syk) and Zeta-chain-associated protein kinase 70 (ZAP70), have also been excluded. Thus, mutations in either the ligand-binding receptor or the signaling adapter protein of a myeloid cell immunoreceptor signaling complex, TREM2 or DAP12, are associated with Nasu–Hakola disease.

### TREM2 and DAP12 expression

DAP12 is expressed in most innate immune cells including macrophages, monocytes, dendritic cells, granulocytes, and natural killer cells. DAP12 is also found to be expressed in some cells of the adaptive immune system, including subsets of T cells include γδ T cells and CD8+ αβ T cells and some activated B cells where DAP12 negatively mediates B cell immune responses. Interestingly, γδ T cells function as innate-type T cells with an invariant T cell receptor and the ability to respond to pathogen-associated molecular patterns similar to innate immune cells. OCs, also derived from myeloid precursors, express DAP12. Like DAP12, TREM2 is expressed in cells of the myeloid lineage including macrophages, OCs, and dendritic cells.

In the brain, DAP12 and TREM2 are mainly expressed in microglial cells derived from myeloid precursors. Microglia are the most abundant cells in the brain and responsible for immune surveillance of the brain. TREM2 is highly transcribed in resting unstimulated microglia and is downregulated by lipopolysaccharides and interferon-γ. In humans, TREM2 expression in brain tissue is highest in white matter and lowest in cerebellum and increases with age in the substantia nigra, thalamus, and medulla. In mice, TREM2 expression in microglia is more heterogeneous with the highest expression in the cingulate cortex and lateral entorhinal cortex and relatively little expression in regions with an incomplete blood–brain barrier including the hypothalamus, circumventricular organs, and the median eminence.

### Table 1 TREM2 and TYROBP mutations identified in PLOS1

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Location</th>
<th>TREM2/TYROBP function change</th>
<th>Country</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TYROBP</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Del 5.3 kb</td>
<td>Exons 1–4</td>
<td>No TYROBP expression</td>
<td>Finland, Norway, Sweden</td>
<td>12</td>
</tr>
<tr>
<td>Del 8B kb</td>
<td>Exons 1–4</td>
<td>No TYROBP expression</td>
<td>Brazil</td>
<td>13</td>
</tr>
<tr>
<td>141 DelG</td>
<td>Exon 3</td>
<td>Frame shift, truncated DAP12 protein</td>
<td>Japan</td>
<td>12, 18</td>
</tr>
<tr>
<td>2 T→C</td>
<td>Exon 1</td>
<td>Met1Thr, no TYROBP expression</td>
<td>Japan</td>
<td>18</td>
</tr>
<tr>
<td>145 G→C</td>
<td>Exon 3</td>
<td>Nonfunctional truncated DAP12</td>
<td>Portugal</td>
<td>20</td>
</tr>
<tr>
<td>262 G→T</td>
<td>Exon 4</td>
<td>Glu87Stp</td>
<td>Japan</td>
<td>19</td>
</tr>
<tr>
<td>154–155ins42nt</td>
<td>Exon 3</td>
<td>Insertion of 14 aa</td>
<td>UK</td>
<td>21</td>
</tr>
<tr>
<td><strong>TREM2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40 G→T</td>
<td>Exon 1</td>
<td>Nonfunctional TREM2</td>
<td>Germany</td>
<td>26</td>
</tr>
<tr>
<td>97 C→T</td>
<td>Exon 2</td>
<td>Glu33Stp, truncated TREM2 protein</td>
<td>Belgium, Italy</td>
<td>13</td>
</tr>
<tr>
<td>132 G→A</td>
<td>Exon 2</td>
<td>Truncated TREM2 protein</td>
<td>Bolivia</td>
<td>13</td>
</tr>
<tr>
<td>267 DelG</td>
<td>Exon 2</td>
<td>Frame shift</td>
<td>France</td>
<td>21</td>
</tr>
<tr>
<td>313 DelG</td>
<td>Exon 2</td>
<td>Frame shift</td>
<td>Germany</td>
<td>21</td>
</tr>
<tr>
<td>377 T→G</td>
<td>Exon 2</td>
<td>Val126Gly</td>
<td>Canada, UK</td>
<td>21</td>
</tr>
<tr>
<td>401 A→G</td>
<td>Exon 3</td>
<td>Asp134Gly, truncated TREM2 protein</td>
<td>USA</td>
<td>13</td>
</tr>
<tr>
<td>482+2 T→C</td>
<td>Intron 3</td>
<td>Splicing mutation, no functional TREM2</td>
<td>Italy</td>
<td>13</td>
</tr>
<tr>
<td>558 G→A</td>
<td>Exon 4</td>
<td>TREM2 DAP12 no interaction</td>
<td>Norway</td>
<td>13</td>
</tr>
</tbody>
</table>

**Abbreviations**: TREM2, triggering receptor expressed on myeloid cells-2; PLOS1, polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy; Del, deletion; Stp, stop codon; aa, amino acid; DAP12, DNAX-activating protein 12.
to the diversity of macrophages and dendritic cells in the periphery.

TREM2 and DAP12 expression detected by immunohistochemistry has also been reported on a fraction of neurons and oligodendrocytes. However, there is controversy as to whether TREM2 and DAP12 are expressed in oligodendrocytes with some studies reporting expression in mouse and the human oligodendrocytes and others reporting the absence of expression. The differences in these studies could be due to several possibilities including alternative approaches in vivo tissue staining versus cell culture of primary cells that may have microglial contamination. Additionally, a soluble form of TREM2 is generated, and it may bind to ligands, such as heat shock protein 60 (HSP60), on neurons and oligodendrocytes and would be detected as TREM2 surface staining by immunohistochemistry. Neither TREM2 nor DAP12 expression has been detected in astrocytes. Thus, TREM2 and DAP12 are expressed in microglia and OCs, the two cell types believed to play substantial roles in PLOS1 pathogenesis.

TREM2 and DAP12 intracellular signaling

TREM2 and DAP12, associated via charged residues within the transmembrane region, are expressed on the plasma membrane of myeloid cells and microglial. DAP12 forms a homodimer linked by two cysteines in the extracellular domain and is believed to associate with one TREM2 receptor based on previous studies of other DAP12-associated receptors (Figure 1). The cytoplasmic domain of DAP12 contains an immunoreceptor tyrosine-based activation motif (ITAM), with the consensus sequence YxxL/Ix6-8YxxL/I (where x represents any aa), that facilitates recruitment and activation of downstream effector molecules. As diagramed in Figure 2, following receptor activation, Src protein tyrosine kinases phosphorylate DAP12 at the two conserved tyrosine residues within the ITAM providing a docking site for the Src homology 2 (SH2) domains of Syk and ZAP70 kinases. Stimulation of TREM2 also induces the co-localization of DAP10 with DAP12 and is required for TREM2-dependent activation of phosphatidylinositol-3 kinase (PI3K). PI3K then converts phosphatidylinositol-4,5-bisphosphate (PIP2) into phosphatidylinositol-3,4,5-trisphosphate (PIP3) leading to the recruitment of the scaffolding protein, linker for the activation of B cells (LAB). LAB subsequently recruits a protein complex consisting of phospholipase C gamma (PLC-γ), SH2 domain-containing leukocyte protein of 76 kDa (SLP-76), guanine nucleotide exchange factor VAV, Tec kinases, growth factor-receptor-bound protein 2 (Grb2), and son of sevenless homolog1 (SOS1). PLC-γ hydrolyzes the membrane lipid PIP2 to secondary messengers diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3). The production of DAG activates two major signaling molecules, protein kinase C (PKC) and Ras guanyl nucleotide-releasing proteins (RasGRPs), which initiate the NF-kB and mitogen-activated protein kinase (MAPK) pathways. IP3 increases calcium mobilization leading to activation of calcium-dependent kinases such as calmodulin-dependent kinase (CaMK), Pyk2, and calcineurin which dephosphorylates members of the nuclear factor-activated T-cell (NFAT) family and induces their nuclear translocation. Thus, DAP12 signaling induces activation of downstream signals including MAPK, PI3K, PKC, and intracellular calcium flux. Other studies have shown that TREM2 and DAP12 are required for reactive oxygen species formation in response to bacteria. These signaling events in myeloid cells lead to cellular differentiation, activation, migration, cytokine production, and phagocytosis.

Interestingly, in macrophages and OCs, TREM2 and DAP12 can also recruit SH2 domain-containing inositol phosphatase-1 (SHIP1) to DAP12’s mono- and bi-phosphorylated ITAM. During tonic ITAM signaling induced by weak or monovalent ligands, SHIP1 prevents PI3K recruitment to limit excessive downstream activation (Figure 2). During strong receptor activation by TREM2 receptor cross-linking, SHIP1 and Syk are recruited to DAP12 and compete for ITAM binding. In the absence of SHIP1, Syk and PI3K activation is increased leading to enhanced ERK, VAV, and AKT activation as well as calcium flux. In macrophages, TREM2 and DAP12 signaling also recruits downstream of kinases 3 (DOK3). DOK3 subsequently binds Grb2 and SOS1, sequestering them, and limiting ERK activation. CBL-b, activated by Syk, then ubiquitinates DOK3 leading to DOK3, Grb2, and SOS1 degradation in the proteasome. Cbl also ubiquitinates Syk leading to degradation of Syk in the proteasome. In B cells, SH2 domain-containing protein tyrosine phosphatase 1 (SHP-1) can also be recruited to DAP12 and also serves an inhibitory function. Whether these downstream regulatory mechanisms contribute to microglial and OC dysfunction in PLOS1 has not been explored.

TREM2 and DAP12 molecular complex also has significant cross talk with other signaling pathways including growth factor receptors, integrins, and Toll-like receptors (TLRs). Macrophage colony-stimulating factor (MCSF) binding to its receptor, c-Fms, induces Src activation, DAP12 phosphorylation, and Syk activation leading to...
myeloid proliferation.\textsuperscript{42,43} Integrin signaling also induces phosphorylation of DAP12 leading to activation of ERK, PLC-\(\gamma\), and VAV required for cytoskeletal reorganization.\textsuperscript{44,45} Additionally, TREM2 and DAP12 inhibit low-level TLR ligand-induced cytokine responses in myeloid cells leading to reduced pro-inflammatory cytokines and inflammation. Thus, TREM2 and DAP12 play several key roles in many vital signaling pathways controlling cellular differentiation, survival, or function.

**TREM2 receptor cycling**

In microglia, TREM2 is localized on the plasma membrane and in the Golgi complex. Phagocytic receptor recycling or ectodomain shedding regulates cell surface expression of TREM2, a process that leads to soluble TREM2 (sTREM2) release from the cell.\textsuperscript{46} TREM2 is recycled to and from the cell surface in endocytic and exocytic vesicles upon stimulation by ionomycin or interferon-\(\gamma\).\textsuperscript{47} TREM2 is also actively regulated by ectodomain shedding of the extracellular ligand-binding domain by a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) followed by intramembranous cleavage of the remaining C-terminal transmembrane domain and intracellular domain by \(\gamma\)-secretase.\textsuperscript{46,48} Inability to fully process the TREM2 C-terminal domain by blocking \(\gamma\)-secretase activity leads to accumulation of membrane-bound nonfunctional TREM2 fragments lacking the extracellular domain inappropriately coupled to DAP12, thereby decreasing the availability of...
DAP12 to couple with functional TREM2 molecules. This is predicted to result in a dominant-negative TREM2-DAP12 complex. Indeed, accumulation of these dysfunctional complexes leads to reduced DAP12 phosphorylation and decreased PI3K activation.

Recent studies by Park et al have revealed that TREM2 mutations seen in PLOSLO have altered trafficking from the endoplasmic reticulum (ER) and Golgi to the plasma membrane. The defective trafficking is associated with impaired TREM2 glycosylation with complex oligosaccharides. As a result, mutant TREM2 proteins accumulate in the ER or Golgi and have reduced plasma membrane expression. In comparison, TREM2 mutant R74H, associated with Alzheimer’s disease (AD), has near normal expression and trafficking but altered glycosylation. The severely reduced TREM2 receptor expression seen in PLOSLO mutants likely contributes to the early onset of central nervous system (CNS) disease compared to late onset with the more normal Alzheimer’s-associated TREM2 mutant R47H.

The role of the cleaved sTREM2 in the cerebrospinal fluid (CSF) is not known, but levels appear to be altered in correlation with CNS diseases. CSF sTREM2 levels are markedly elevated in patients with multiple sclerosis and inflammatory CNS disease compared to those with non-inflammatory CNS disease. Additionally, patients with AD and FTD have significantly decreased sTREM2 in CSF, suggesting that reduced TREM2 function may contribute to increased risk for these neurodegenerative disorders as well. Indeed, heterozygous missense mutations in TREM2 are related to AD, Parkinson’s disease, amyotrophic lateral sclerosis, and FTD. Whether TREM2 receptor is processed correctly in PLOSLO patients lacking DAP12 is unknown.

**TREM2 and DAP12 mediate OC development and function**

TREM2-DAP12 signaling plays an important role in both the innate and the adaptive immune systems. In microglia, TREM2-DAP12 is involved in cell survival, phagocytosis, and actin reorganization required for cell activation and phagocytic activity. TREM2-DAP12 signaling promotes OC and microglia differentiation by modulating precursor responsiveness to certain cytokines and growth factors along with reinforcing cytokine-induced and integrin-triggered signaling pathways.

DAP12 and TREM2 play an important role in osteoclastogenesis and bone-remodeling homeostasis. Loss of function in human DAP12 or TREM2 peripheral monocytes results in inefficient and delayed OC differentiation in response to receptor activator of NF-κB ligand (RANKL). These defective OCs also have reduced bone resorption capacity in vitro; however, PLOSLO bone lesions are of an osteoporotic nature with loss of trabeculae. Similar to OC derived from PLOSLO patients, mice deficient in DAP12 have defective OC development with decreased OC multi-nucleation and decreased function in vitro. However, these mice fail to develop cystic osseous lesions in the bones and have mild osteopetrosis in vivo. Thus, the role of DAP12 in OC is similar in vitro but differs in vivo between mouse and man.

TREM2 and DAP12 also mediate OC fusion and migration. When TREM2 is highly expressed in RAW264.7 pre-osteoclastic cells, TREM2 cross-linking leads to increased multi-nucleation, migration, and survival of mouse OCs. Similarly, when TREM2 is reduced by RNA interference, RAW264.7 have significantly decreased OC potential and reduced multi-nucleation. However, TREM2 deficiency in mice leads to accelerated osteoclastogenesis in vitro and osteopenia in vivo. TREM2-deficient mice, however, do not develop osseous bone lesions. Of note, although TREM2-deficient mice do not produce full-length TREM2, sTREM2 may be present and may have additional effects on OC in vitro. The differences in bone and OC phenotypes in DAP12-deficient and TREM2-deficient mice compared to PLOSLO patients are not fully understood at this time. Alternative immunoreceptor and adapter proteins expressed between human and mouse cells or the effects of sTREM2 could contribute to the different pathologies seen.

**TREM2 and DAP12 mediate innate immune responses**

The function of TREM2 and DAP12 in innate immune cells is complex with both immune activation and inhibitory functions (Figures 1 and 2). While DAP12 is expressed constitutively in most myeloid cells, TREM2 expression is upregulated in M2-polarized macrophages that promote tissue repair. TREM2 expression is also upregulated in tissue macrophages infiltrating across an endothelial barrier and by MCSF and interleukin-4 important for regulation of chronic inflammation. Additionally, TREM2-DAP12 plays a role in maturation and survival of human dendritic cells, as well as in dendritic cell migration.

Since DAP12 promotes pro-inflammatory responses when coupled to other DAP12-associated receptors such as TREM1 and MDL1, TREM2-DAP12 was expected to enhance pro-inflammatory responses. Surprisingly, TREM2-DAP12 inhibits TLR-induced pro-inflammatory cytokine responses in macrophages and dendritic cells (Figure 2).
Whereas DAP12 mediates the majority of TLR ligand responses, TREM2 is required to dampen more selective TLR ligands including lipopolysaccharides (TLR4), zymosan (TLR2/6), and CpG (TLR9). The inhibition of TLR responses by TREM2 is dependent on the expression and coupling to functional DAP12. Thus, TREM2 and DAP12 function together to limit TLR-induced pro-inflammatory responses in macrophages and dendritic cells.

**TREM2-DAP12 mediates microglia function**

Perhaps in an analogous manner, TREM2 expression on microglia promotes phagocytosis of apoptotic neurons and bacteria without eliciting an immune response. TREM2 expression promotes phagocytosis of apoptotic neurons presumably by recognition of a ligand expressed during apoptosis. When TREM2 is expressed on microglia, it has enhanced phagocytosis of apoptotic neurons and does so with minimal pro-inflammatory cytokine production. In the absence of TREM2, apoptotic neurons promote excessive microglial activation and pro-inflammatory responses leading to CNS inflammation. TREM2-DAP12 is also important for efficient microglial phagocytosis of amyloid deposits.

Thus, abnormalities in TREM2 or DAP12 in human PLOSL microglia are expected to inhibit clearance of apoptotic neurons and amyloid deposits.

Importantly to its role in promoting and inhibiting immune responses, TREM2 functions as a pattern-recognition receptor and can bind to a variety of bacterial cell wall products, lipids, and anionic ligands. Engagement of these ligands with TREM2 promotes phagocytosis. Despite recognition of TREM2 ligands on macrophages, neuroblastomas, and apoptotic neurons by TREM2 fusion proteins, endogenous TREM2 ligands remain largely unknown. One exception is HSP60, a mitochondrial protein chaperone, which becomes expressed on the plasma membranes of apoptotic neurons.

TREM2-dependent microglial clearance of apoptotic neurons is significantly increased by HSP60 and may serve as a trigger for TREM2-mediated phagocytosis. Interestingly, HSP60 is also an endogenous ligand for TLR4 and induces tumor necrosis factor-α and nitric oxide in macrophages. Therefore, HSP60 could induce an inflammatory response bound to TLR4 or could lead to suppression of TLR4-induced cytokines when bound to TREM2. Additional studies are required to test this hypothesis, but recently studies have found mutations in Hspd1, the gene encoding HSP60, associated with two human nervous system diseases including spastic paraplegia and an autosomal recessively inherited hypomyelinating leukodystrophy termed MitCHAP60.

Supporting the role of HSP60 in normal brain function, mice haploinsufficient for HSP60 were recently shown to develop late-onset neurodegeneration. More studies are needed to determine the role of HSP60 in microglial responses.

TREM2 has also been shown to pair with plexin-A1, a semaphorin 6D (Sema6D)-binding receptor important for axon guidance, cardiac morphogenesis, and dendritic cell function. TREM2 and plexin-A1 can associate independently of DAP12; thus, TREM2 appears to function as a bridge to bring plexin-A1 together with DAP12. Sema6D enhances osteoclastogenesis in vitro, but Sema6D binding to OCs does not require TREM2 indicating that Sema6D is not a TREM2 ligand per se. However, plexin-A1-deficient mice develop high bone mass due to decreased OCs similar to DAP12-deficient mice. Importantly, no nervous system changes were found in plexin-A1-deficient mice indicating that TREM2-DAP12 coupled with plexin-A1 is not required for brain homeostasis. Further studies are required to define a role, if any, of this tri-molecular complex in microglia.

**TREM2-DAP12 dysfunction in PLOSL**

Although the exact molecular mechanisms of the development of leukoencephalopathy in brains of PLOSL patients are unknown, abnormalities in TREM2-DAP12 regulation of microglial inflammatory responses and clearance of neuronal and amyloid debris appear to be central to the cause. In PLOSL, TREM2 or DAP12 deficiency is postulated to lead to excessive microglial pro-inflammatory activation with decreased clearance of neuronal debris leading to neurodegeneration. DAP12- or TREM2-deficient microglia fail to remove apoptotic neurons, and thus induce inflammation of the brain, amyloid plaque deposition, and early FTD seen in PLOSL.

PLOSL brains also show loss of myelin, accumulation of axonal spheroids, and profound gliosis. During periods of cellular distress or tissue repair, oligodendrocyte autophagy is required to maintain myelin sheaths. Perhaps, the loss of myelin in PLOSL results from dysfunctional oligodendrocytes autophagy induced by abnormal TREM2- or DAP12-deficient microglia. Alternatively, loss of TREM2-DAP12 signaling in oligodendrocytes themselves could contribute to oligodendrocyte apoptosis or a defect in oligodendrocyte function leading to loss of myelin maintenance. In support of this hypothesis, DAP12-deficient mice and DAP12-loss-of-function (Ka75) transgenic mice expressing mutation of tyrosine 75 (Y75) within the DAP12 ITAM have decreased myelin.
DAP12-deficient mice also have decreased oligodendrocytes, whereas the KA75 mice have decreased microglia but normal oligodendrocytes.\textsuperscript{37,75} Interestingly, phosphorylated Syk, the downstream effector of DAP12 signaling, is significantly increased in neurons and microglia of PLOS\textsubscript{L} brains compared to control brains.\textsuperscript{76} This finding suggests uncontrolled Syk activation in the absence of TREM2 and DAP12 and is compatible with increased microglial activation.

The recent findings that rare TREM2 variants are associated with FTD without bone lesions, AD, and Parkinson’s disease provide additional insight into the role of TREM2 in brain homeostasis.\textsuperscript{77–80} Although it is not clear how TREM2 mutations contribute to AD, many of these rare variants lead to point mutations in the TREM2 ligand-binding domain or to the inability to effectively shed TREM2 from plasma membranes leading to accumulation of dysfunctional TREM2 fragment-DAP12 complexes.\textsuperscript{81} These TREM2 fragment-DAP12 complexes could function as a dominant negative form of the receptor complex. TREM2 is highly expressed in AD brain tissue, especially surrounding amyloid plaques. As discussed earlier, TREM2 can mediate amyloid plaque phagocytosis; therefore, it is tempting to speculate that dominant-negative TREM2 mutants seen in AD fail to phagocyte amyloid resulting in a similar amyloid-associated Alzheimer’s-type dementia seen in PLOS\textsubscript{L} when TREM2 or DAP12 is absent. Both conditions would lead to inappropriate pro-inflammatory microglial activation and accumulation of amyloid-β plaques.

To test this hypothesis, Ulrich et al recently examined the role of TREM2 haploinsufficiency in the APPPS\textsubscript{1-21} mouse model of AD.\textsuperscript{81} They found that TREM2 haploinsufficient APPPS\textsubscript{1-21} mice had decreased number and size of plaque-associated microglia at 3 months, suggesting that microglial responses to amyloid plaque are regulated by TREM2. However, no significant differences in inflammatory cytokines or total amyloid plaque burden were seen in TREM2 heterozygotes compared to TREM2\textsuperscript{+/-} mice. A recent study has shown that two point mutations in TREM2 seen in PLOS\textsubscript{L} have abnormal TREM2 glycosylation leading to accumulation in the ER and Golgi with decreased surface expression.\textsuperscript{82} The AD mutant R74H had normal trafficking but altered glycosylation compared to wild type. This suggests that the glycosylation pattern of TREM2 is critical for normal function and that it is not just the level of TREM2 expressed. These results would then predict normal brain function in TREM2 haploinsufficiency.

Amyloid-β deposits are recognized in part by a molecular complex of TLR4 and TLR6 in conjunction with CD36.\textsuperscript{82,83} This molecular complex is required for recognition and uptake of amyloid and induces activation of Src family kinase-mediated intracellular signals resulting in pro-inflammatory cytokine production.\textsuperscript{82} Given the strong evidence supporting the role of TREM2 and DAP12 inhibiting TLR signals, we speculate that in the absence of TREM2 or DAP12 in PLOS\textsubscript{L}, amyloid-stimulated TLR activation is uninhibited, leading to excessive activation of microglia with poor ability to phagocytize apoptotic neurons or amyloid deposits. Similarly, in AD, the accumulation of dysfunctional TREM2 fragment-DAP12 complexes or impaired ligand binding by TREM2 mutants would result in the inability to effectively inhibit the pro-inflammatory cytokine responses induced by amyloid-β. As discussed above, TREM2 and DAP12 associate with inhibitory proteins SHIP1 and DOK3 to mediate inhibition of Syk, PI3K, and ERK activation as well as limit TLR responses in macrophages. The role of this inhibitory pathway in PLOS\textsubscript{L} or AD has not been explored. Thus, further studies looking at the activation state and subcellular location of these proteins in PLOS\textsubscript{L} or AD microglia in response to amyloid may be informative as to the inhibitory function of DAP12 in these settings.

Recent studies have attempted to find biomarkers that could serve to aid the diagnosis of PLOS\textsubscript{L}. Giuliano et al performed proteomic analysis comparing Epstein–Barr virus-transformed B cells from seven Nasu–Hakola patients and five healthy controls.\textsuperscript{84} They found 21 differentially expressed proteins in the B cells from affected patients. Many of these proteins are involved in glucose metabolism and stress responses and suggest that energy metabolism of the brain may be altered in PLOS\textsubscript{L}. However, no definitive biomarkers have yet been identified specific for PLOS\textsubscript{L}.

Despite our significant knowledge on the roles of TREM2 and DAP12 in human and mouse osteoclastogenesis and mouse bone remodeling, it remains a mystery why PLOS\textsubscript{L} patients develop cystic bone lesions filled with folded membranes and degenerated fatty tissue. The lesions progress from early loss of trabeculae to a poorly formed, non-sclerotic cyst. The early progressive loss of trabeculae could be the result of excessive OC activity as seen in the TREM2 knock-out mice, but this does not explain the accumulation of lipid bilayers and fatty tissue. Additional molecular analysis of the contents of the cysts has not yet been performed, so it is not known if there are substantial adipocyte-associated macrophages present in the cystic fat tissues that could be pathological. TREM2 has been reported to be increased in adipose tissue from obese dogs compared to lean ones and in obese diabetic db/db mice.\textsuperscript{85,86} Therefore, it is possible that...
TREM2 could be regulated by adipocytes or participate in adipocyte regulation. If so, then TREM2 deficiency could lead to adipocyte degeneration or dysfunction. In support of this hypothesis, TREM2-transgenic mice fed a high-fat diet became more obese with increased adipocyte hypertrophy than control mice on a high-fat diet. The role of TREM2 and DAP12 in adipocytes, adipose tissue macrophages, or metabolic programming of myeloid cells has not been explored at this time.

**Summary**

PLOSL is a complex disease with significant disorder in the brain and bones. Genetic analysis has identified mutations in two genes, **TYROBP** and **TREM2**, resulting in loss of function of the TREM2-DAP12 immunoreceptor signaling complex. Genetic analysis of the genes for TREM2 and DAP12 remains the current gold standard for identification of Nasu–Hakola. Early studies suggest that TREM2-DAP12 is required for microglia phagocytosis of neuronal debris and amyloid deposits. In the absence of this complex, microglia become excessively activated, amyloid deposits accumulate, and there is myelin loss in the brain. In the bones, cystic bone lesions filled with lipid bilayers develop and result in pathological fractures and pain. While helpful, mouse models of PLOSL recapitulate some but not all features of PLOSL. Additional studies are needed to understand the role of TREM2-DAP12 in normal and pathological CNS diseases.

**Author contributions**

All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


